Show simple item record

Targeting of the Mitochondrial TET1 Protein by Pyrrolo[3,2-b]pyrrole Chelators

dc.contributor.authorAntonyová, Veronika
dc.contributor.authorTatar, Ameneh
dc.contributor.authorBrogyányi, Tereza
dc.contributor.authorKejík, Zdeněk
dc.contributor.authorKaplánek, Robert
dc.contributor.authorVellieux, Frédéric
dc.contributor.authorAbramenko, Nikita
dc.contributor.authorSinica, Alla
dc.contributor.authorHajduch, Jan
dc.contributor.authorNovotný, Petr
dc.contributor.authorMasters, Bettie Sue
dc.contributor.authorMartásek, Pavel
dc.contributor.authorJakubek, Milan
dc.date.issued2022
dc.identifier.urihttps://hdl.handle.net/20.500.14178/1688
dc.description.abstractTargeting of epigenetic mechanisms, such as the hydroxymethylation of DNA, has been intensively studied, with respect to the treatment of many serious pathologies, including oncological disorders. Recent studies demonstrated that promising therapeutic strategies could potentially be based on the inhibition of the TET1 protein (ten-eleven translocation methylcytosine dioxygenase 1) by specific iron chelators. Therefore, in the present work, we prepared a series of pyrrolopyrrole derivatives with hydrazide (1) or hydrazone (2-6) iron-binding groups. As a result, we determined that the basic pyrrolo[3,2-b]pyrrole derivative 1 was a strong inhibitor of the TET1 protein (IC50 = 1.33 mu M), supported by microscale thermophoresis and molecular docking. Pyrrolo[3,2-b]pyrroles 2-6, bearing substituted 2-hydroxybenzylidene moieties, displayed no significant inhibitory activity. In addition, in vitro studies demonstrated that derivative 1 exhibits potent anticancer activity and an exclusive mitochondrial localization, confirmed by Pearson's correlation coefficient of 0.92.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.3390/ijms231810850
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titleTargeting of the Mitochondrial TET1 Protein by Pyrrolo[3,2-b]pyrrole Chelatorsen
dcterms.accessRightsopenAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2023-10-02T06:12:36Z
dc.subject.keywordTET1 protein inhibitoren
dc.subject.keywordpyrrolo[3en
dc.subject.keyword2-b]pyrroleen
dc.subject.keywordhydrazoneen
dc.subject.keywordmitochondriaen
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/LM/LM2015062
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/OP VVV/CZ.02.1.01/0.0/0.0/16_013/0001775
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MPO/FV/FV40120
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5102
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5107
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/SVV/SVV260521
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/UNCE/MED/UNCE/MED/007
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/LM/LM2018133
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/TA0/TN/TN01000013
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/TA0/FW/FW02020128
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/EF/EF16_019/0000785
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/OP VVV/CZ.02.1.01/0.0/0.0/16_019/0000785
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU21-08-00407
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU22-08-00160
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/FN/I-FN/RVO-VFN64165
dc.date.embargoStartDate2023-10-02
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.3390/ijms231810850
dc.identifier.utWos000858770200001
dc.identifier.eidScopus2-s2.0-85138892878
dc.identifier.obd616216
dc.identifier.rivRIV/00216208:11110/22:10448557
dc.identifier.rivRIV/00064165:_____/22:10448557
dc.identifier.rivRIV/00064165:_____/22:10448557
dc.identifier.pubmed36142763
dc.subject.rivPrimary10000::10600
dcterms.isPartOf.nameInternational Journal of Molecular Sciences
dcterms.isPartOf.issn1661-6596
dcterms.isPartOf.journalYear2022
dcterms.isPartOf.journalVolume23
dcterms.isPartOf.journalIssue18
uk.faculty.primaryId108
uk.faculty.primaryName1. lékařská fakultacs
uk.faculty.primaryNameFirst Faculty of Medicineen
uk.faculty.secondaryId53
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazecs
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazeen
uk.department.primaryId100025448551
uk.department.primaryNameBIOCEV 1. LF UKcs
uk.department.primaryNameBIOCEVen
uk.department.secondaryId1522
uk.department.secondaryId1496
uk.department.secondaryId5000002603
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1. LF a VFNcs
uk.department.secondaryNameDepartment of Paediatrics and Inherited Metabolic Disorders 1. LF UK a VFNen
uk.department.secondaryNameÚstav patologické fyziologie 1. LF UKcs
uk.department.secondaryNameInstitute of Pathological Physiologyen
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1.LF a VFNcs
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1.LF a VFNen
dc.description.pageRangenestránkováno
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::původní článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::original articleen
dc.type.obdHierarchyCode73::152::206en
uk.displayTitleTargeting of the Mitochondrial TET1 Protein by Pyrrolo[3,2-b]pyrrole Chelatorsen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record